To illustrate the role of Rezūm convective water vapor ablation for treatment of lower urinary tract symptoms secondary to BPH.
A prospective registry was established for Rezūm therapy in Canada at two high-volume centers.
All patients had baseline medical and BPH history documented, along with uroflowmetry and validated questionnaires up to 12 months post-surgery.
229 patients (mean age 67.3 years), including 83 with prostate volumes ≥ 80 mL, were treated from April 2019 to December 2020. The mean prostate volume was 71.5mL (range 20-160mL) and 55% had a median lobe. The mean number of injections was 11 (range: 4-28) and mean procedural length was 4.8 minutes (range: 1.5-14). The mean duration of post-procedure catheterization was 9.8 days. IPSS scores improved from baseline by 29%, 53%, and 59% at 1, 3, and 12 months, respectively. IPSS QoL improved from baseline by 30%, 50%, and 67% at 1, 3, and 12 months, respectively. Qmax improved by 60% at 3 months and 74% at 12 months. PVR improved by 51% and 61% at 3 and 12 months, respectively. No statistically significant changes were seen in IIEF-15 or MSHQ-EjD scores. No Clavien-Dindo events ≥ Grade III occurred.
Rezūm therapy is a safe, effective, and quick outpatient procedure for prostate glands over a wide range of volumes. Clinically significant improvements are seen in all validated questionnaires. Objective maximum flow measures improved, while erectile and ejaculatory function remains preserved.
Urology. 2022 Feb 16 [Epub ahead of print]
Dean Elterman, Naeem Bhojani, Christopher Vannabouathong, Bilal Chughtai, Kevin C Zorn
Division of Urology, University Health Network, University of Toronto, Toronto, Canada. Electronic address: ., University of Montreal Hospital Center, Université de Montréal, Montreal, Canada., Division of Urology, University Health Network, University of Toronto, Toronto, Canada., Department of Urology, Weill Cornell Medical College, New York Presbyterian, New York, USA.